Benzoyl peroxide cleansers for the treatment of acne vulgaris: Status report on available data

Cutis

Volumn 82, Issue 5, 2008, Pages 336-342

  Del Rosso, James Q ^a,b,c  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

^b Las Vegas Skin and Cancer Clinics   (United States)

^c Las Vegas Skin and Cancer Clinics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BENZOYL PEROXIDE; DERMATOLOGICAL AGENT;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG COMBINATION; DRUG EFFECT; HUMAN; INTRADERMAL DRUG ADMINISTRATION; PROPIONIBACTERIUM ACNES;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; DERMATOLOGIC AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; PROPIONIBACTERIUM ACNES;

EID: 58149399184     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Gollnick H, Cunliffe W, Berson D, et al; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.
2. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79(suppl 6):9-25.
3. Leyden JJ, Kaidbey K, Gans EH. The antimicrobial effect in vivo of minocycline, doxycycline and tetracycline in humans. J Dermatol Treat. 1996;7:223-225.
4. Leyden JJ. Current issues in antimicrobial therapy for treatment of acne. J Eur Acad Dermatol Venereol. 2001;15 (suppl 3):51-55.
5. Leyden JJ. The evolving role of Propionibacterium acnes in acne. Sem Cutan Med Surg. 2001;20:139-143.
6. Del Rosso JQ. Keeping it clean. Skin & Aging. 2003;11: 80-85.
7. Del Rosso JQ. Benzoyl peroxide cleansers. Presented at: The Scientific Panel on Antibiotic Use in Dermatology; November 8-10, 2007; Las Vegas, NV.
8. Smith EW, Surber C, Tassopoulis T, et al. Topical dermatological vehicles: a holistic approach. In: Bronaugh RL, Maibach HI, eds. Topical Absorption of Dermatological Products. Marcel Dekker: New York, NY; 2002:457-463.
9. Data on file. Mills OH, Rafal E, Hino P, et al. Evaluating the efficacy of benzoyl peroxide wash. Fort Worth, TX: Galderma Laboratories, LP; 2002.
10. Data on file. Leyden JJ, Kaidbey K. Evaluation of the antimicrobial effects in vivo of benzoyl peroxide cleanser (Triaz) in humans. Scottsdale, AZ: Medicis Pharmaceutical Corporation; 2002.
11. Leyden JJ, Gans E. Antimicrobial effects of benzoyl peroxide (Triaz), clindamycin 1% lotion (Cleocin T) and azelaic acid 20% cream (Azelex) in humans. J Dermatol Treat. 1997;2(suppl):S7-S10.
12. Kligman AM, Gans EH. Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes. J Dermatol Treat. 2002;13: 107-110.
13. Cunliffe WJ, Holland KT, Bojar R, et al. A randomized, double-blind comparison of a clindamycin phosphate/ benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24:1117-1133.
14. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Austral. 1998;169:259-261.
15. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? implications of resistance for acne patients and prescribers. Am J Clin Dermatol. 2003;4:813-831.
16. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A, Japan and Australia. Br J Dermatol. 2001;144:339-346.
17. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003;148:467-478.
18. Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol. 1989;121:51-57.
19. Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol. 2002;146:840-848.
20. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol. 2005;153:395-403.
21. Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol. 2008;158:208-216.
22. Leyden JJ, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes: an in vivo comparative study. Am J Clin Dermatol. 2001;2:263-266.
23. Leyden JJ. The effect of benzoyl peroxide 6% wash on antibiotic-resistant Propionibacterium acnes. Poster presented at: 31st Hawaii Dermatology Seminar; Maui, HI; March 3-9, 2007.
24. Shalita AR, Rafal ES, Anderson D, et al. Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis. 2003;72:167-172.
25. Del Rosso JQ, Bikowski JB, Baum E, et al. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol. 2007;6:597-600.
26. Gold M. Survey results of compliance, preference, and satisfaction in patients prescribed benzoyl peroxide 8% wash and benzoyl peroxide 9% cleanser for the treatment of acne vulgaris. Poster presented at: American Academy of Dermatology 64th Annual Meeting; San Francisco, CA; March 3-7, 2006.
27. Data on file. Testing retention of benzoyl peroxide cleanser in vitro percutaneous absorption study in human cadaver skin. Scottsdale, AZ: Medicis Pharmaceutical Corporation; 2003.